Latest Ratios: P/E Ratio -0.6x · EV/EBITDA N/A · ROE -992.7%. (2002–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $20M | $31M | $30M | $29M | $40M | $111M | $161M | $77M | $129M | $112M | $106M |
| Enterprise Value | $48M | $60M | $53M | $54M | $59M | $105M | $154M | $72M | $120M | $107M | $100M |
| P/E Ratio → | -0.61 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 14.67 | 23.48 | 92.91 | 102.50 | 169.21 | — | 6995.13 | 1418.07 | 2582.50 | — | 37.16 |
| P/B Ratio | — | — | 5.59 | 1.92 | 1.23 | 1.95 | 2.87 | 3.51 | 4.53 | 3.70 | 2.77 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 44.55 | 162.93 | 188.02 | 250.54 | — | 6680.35 | 1342.03 | 2406.08 | — | 34.98 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.0% | 49.0% | 98.8% | 96.9% | -350.0% | — | -6726.1% | 96.3% | 96.0% | — | 96.5% |
| Operating Margin | -1659.9% | -1659.9% | -6796.9% | -9493.4% | -17774.8% | — | -128156.5% | -65800.0% | -67462.0% | — | -819.1% |
| Net Profit Margin | -1690.3% | -1690.3% | -6407.4% | -9867.9% | -17624.8% | — | -126747.8% | -65383.3% | -52252.0% | — | -816.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -992.7% | -992.7% | -201.7% | -119.3% | -92.3% | -88.1% | -74.8% | -140.3% | -88.9% | -81.3% | -48.3% |
| ROA | -57.7% | -57.7% | -46.3% | -47.7% | -51.0% | -62.7% | -60.2% | -100.5% | -68.3% | -66.6% | -40.7% |
| ROIC | -59.9% | -59.9% | -48.8% | -44.9% | -61.3% | -76.4% | -66.4% | -142.5% | -111.9% | -73.1% | -51.9% |
| ROCE | -107.1% | -107.1% | -55.2% | -51.2% | -58.1% | -72.5% | -73.1% | -132.7% | -107.9% | -77.5% | -45.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 5.47 | 1.95 | 0.89 | 0.43 | 0.03 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 4.22 | 1.60 | 0.59 | -0.12 | -0.13 | -0.19 | -0.31 | -0.16 | -0.16 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -25.64 | -25.64 | -23.65 | -33.27 | -45.64 | -638.29 | -147.73 | -1217.48 | -27.88 | — | -233.19 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.68 | 0.68 | 6.98 | 7.37 | 8.46 | 5.85 | 6.07 | 3.23 | 3.75 | 5.36 | 6.16 |
| Quick Ratio | 0.68 | 0.68 | 6.98 | 7.37 | 8.46 | 5.85 | 6.07 | 3.15 | 3.75 | 5.36 | 6.16 |
| Cash Ratio | 0.64 | 0.64 | 6.73 | 7.15 | 8.06 | 5.64 | 5.80 | 2.91 | 3.50 | 4.82 | 5.58 |
| Asset Turnover | — | 0.03 | 0.01 | 0.01 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.06 |
| Inventory Turnover | — | — | — | — | — | — | — | 0.00 | — | — | — |
| Days Sales Outstanding | — | 197.25 | 714.33 | 670.23 | 2060.53 | — | 25550.00 | 9604.91 | 6183.10 | — | 318.08 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $6M | $5M | $5M | $4M | $4M | $2M | $2M | $1M | $1M | $994349 |
Imminent liquidity and solvency
As reported in recent financial filings, Pluri's price-to-sales ratio of 13.67x suggests that the market is pricing the company as a high-growth platform rather than a clinical-stage biotech, despite the lack of consistent, recurring revenue streams to justify such a premium valuation relative to its peers.
The current valuation appears to rely heavily on the potential of the 3D bioreactor IP rather than tangible financial performance. Investors should monitor whether this multiple contracts as the market reconciles the company's pivot to CDMO services with its historical inability to generate sustainable commercial revenue.
Based on reported figures, Pluri's ROIC has remained consistently negative, reaching -22.5% in 2026Q3, which indicates that the company is currently destroying shareholder capital rather than compounding it through its research and development activities or its recent strategic shift toward industrial manufacturing services.
The negative return on capital reflects the structural imbalance between heavy fixed-cost investments in Haifa-based facilities and the lack of corresponding commercial output. This trend suggests that the company's current capital allocation strategy may be unsustainable without a significant improvement in operational efficiency or a major breakthrough in revenue generation.
According to recent quarterly data, Pluri's asset turnover ratio has stagnated at 0.01, highlighting a profound inability to convert its specialized manufacturing infrastructure into meaningful revenue, while the volatility in its cash conversion cycle suggests significant challenges in managing supplier and customer payment terms effectively.
The extremely low asset turnover ratio underscores the underutilization of the company's manufacturing assets. Investors should investigate whether the recent pivot to CDMO services can improve these metrics or if the current infrastructure remains a persistent drag on the company's overall operational efficiency.
As disclosed in recent SEC filings, Pluri's current ratio has plummeted to 0.33 as of 2026Q3, a sharp decline from historical levels, which indicates that the company's ability to meet its short-term obligations is severely compromised and suggests an urgent need for external capital to maintain operations.
The rapid deterioration of the liquidity position leaves little room for error regarding clinical trial timelines or operational disruptions. This vulnerability warrants close monitoring, as the company may be forced to pursue highly dilutive financing options to address its immediate cash requirements and sustain its ongoing research initiatives.
The most commonly misapplied ratio for Pluri is the price-to-sales multiple, which obscures the company's true economic reality by treating non-recurring grant income and milestone payments as sustainable commercial revenue, thereby failing to account for the high probability of future dilution and the lack of operational scale.
Analysts should instead focus on cash burn rates and the remaining runway, as these metrics provide a more accurate assessment of the company's survival prospects. Relying on P/S multiples in a pre-commercial biotech context often leads to an overestimation of value by ignoring the binary nature of clinical and regulatory outcomes.
Includes 30+ ratios · 24 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PLUR stock.
Pluri Inc.'s current P/E ratio is -0.6x. This places it at the 50th percentile of its historical range.
Pluri Inc.'s return on equity (ROE) is -992.7%. The historical average is -157.8%.
Based on historical data, Pluri Inc. is trading at a P/E of -0.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Pluri Inc. has 49.0% gross margin and -1659.9% operating margin.